Bioasis Technologies Inc. (OTCMKTS:BIOAF) Short Interest Down 23.3% in July
Bioasis Technologies Inc. (OTCMKTS:BIOAF) Short Interest Down 23.3% in July
Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) was the recipient of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 34,600 shares, a decrease of 23.3% from the July 15th total of 45,100 shares. Based on an average daily trading volume, of 29,000 shares, the short-interest ratio is presently 1.2 days.
綠洲生物科技股份有限公司(場外交易代碼：BIOAF-GET Rating)是7月份空頭股數銷量大幅下降的接收方。截至7月31日，空頭股數共有3.46萬股，比7月15日的4.51萬股減少了23.3%。以日均成交量2.9萬股計算，目前短息比為1.2天。
Bioasis Technologies Stock Performance
BiOASIS科技股表現
BIOAF stock opened at $0.12 on Monday. The company's 50 day moving average price is $0.13 and its 200 day moving average price is $0.17. Bioasis Technologies has a fifty-two week low of $0.10 and a fifty-two week high of $0.28. The firm has a market capitalization of $9.50 million, a price-to-earnings ratio of -2.99 and a beta of 0.19.
週一，BIOAF的股票開盤報0.12美元。該公司的50日移動均線價格為0.13美元，其200日移動均線價格為0.17美元。BiOasis Technologies的股價為0.10美元，為52周低點，52周高位為0.28美元。該公司市值為950萬美元，市盈率為-2.99倍，貝塔係數為0.19。
Bioasis Technologies (OTCMKTS:BIOAF – Get Rating) last announced its quarterly earnings results on Tuesday, June 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. Equities analysts forecast that Bioasis Technologies will post -0.05 EPS for the current fiscal year.
BiOasis Technologies(OTCMKTS：BIOAF-GET Rating)最近一次公佈季度收益是在6月14日(星期二)。該公司公佈了該季度每股收益(EPS)(0.01美元)。股票分析師預測，BiOasis Technologies本財年的每股收益將達到0.05歐元。
Bioasis Technologies Company Profile
BiOASIS技術公司簡介
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.
BiOASIS技術公司是一家處於發展階段的生物製藥公司，致力於神經疾病和障礙的診斷和治療產品的研究和開發。它正在開發xB3，這是一種通過血腦屏障(BBB)運輸治療劑的平臺技術；以及治療中樞神經系統疾病(CNS)，包括腦癌，以及代謝和神經退行性疾病。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- Here's How the Inflation Reduction Act Energizes Power Stock
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- 免費獲取StockNews.com關於BiOASIS技術的研究報告(BIOAF)
- 以下是一個簡單的4只股票投資組合，它可以跑贏大盤
- AMC娛樂公司是在對猩猩採取快速行動嗎？
- 以下是《降低通脹法案》如何提振電力庫存
- 值得關注的兩場重要的零售股大戰
- MarketBeat：回顧中的一週2012-8-8
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《BiOASIS技術日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對BiOasis Technologies及相關公司的評級的每日摘要。
譯文內容由第三人軟體翻譯。